Sotera Health Appoints Christopher Simon to the Board of Directors
Sotera Health Company (Nasdaq: SHC) has appointed Christopher Simon as a new independent director to its Board of Directors. Simon will serve on the Leadership Development and Compensation Committee. He brings over 30 years of experience in business transformation and growth, currently serving as President and CEO of Haemonetics (NYSE: HAE). Simon's background includes roles at McKinsey & Company, Baxter Healthcare , and as a U.S. Army Infantry Officer.
Michael B. Petras, Jr., Chairman and CEO of Sotera Health, expressed excitement about Simon's addition, citing his leadership experience as a public company CEO and extensive commercial and strategic expertise in the life sciences industry as valuable assets for the company's growth. Simon also serves on the board of directors of AdvaMed, a global medical technology trade association.
Sotera Health Company (Nasdaq: SHC) ha nominato Christopher Simon come nuovo direttore indipendente nel suo Consiglio di Amministrazione. Simon farà parte del Comitato per lo Sviluppo della Leadership e della Compensazione. Porta con sé oltre 30 anni di esperienza nella trasformazione e crescita aziendale, attualmente ricoprendo il ruolo di Presidente e CEO di Haemonetics (NYSE: HAE). Il background di Simon include ruoli presso McKinsey & Company, Baxter Healthcare e come Ufficiale di Fanteria dell'Esercito Statunitense.
Michael B. Petras, Jr., Presidente e CEO di Sotera Health, ha espresso entusiasmo per l'aggiunta di Simon, citando la sua esperienza di leadership come CEO di una società pubblica e la sua vasta competenza commerciale e strategica nel settore delle scienze della vita come risorse preziose per la crescita dell'azienda. Simon è anche membro del consiglio di amministrazione di AdvaMed, un'associazione commerciale globale per la tecnologia medicale.
Sotera Health Company (Nasdaq: SHC) ha nombrado a Christopher Simon como nuevo director independiente en su Junta Directiva. Simon formará parte del Comité de Desarrollo de Liderazgo y Compensación. Aporta más de 30 años de experiencia en transformación y crecimiento empresarial, y actualmente se desempeña como Presidente y CEO de Haemonetics (NYSE: HAE). El historial de Simon incluye roles en McKinsey & Company, Baxter Healthcare y como Oficial de Infantería del Ejército de EE. UU.
Michael B. Petras, Jr., Presidente y CEO de Sotera Health, expresó su entusiasmo por la incorporación de Simon, citando su experiencia de liderazgo como CEO de una empresa pública y su amplia experiencia comercial y estratégica en la industria de ciencias de la vida como activos valiosos para el crecimiento de la empresa. Simon también es miembro de la junta directiva de AdvaMed, una asociación comercial global de tecnología médica.
소테라 헬스 컴퍼니(Nasdaq: SHC)는 크리스토퍼 사이먼을 새로운 독립 이사로 이사회에 임명했습니다. 사이먼은 리더십 개발 및 보상 위원회에서 활동할 예정입니다. 그는 현재 헤모네틱스(NYSE: HAE)의 사장 겸 CEO로서 30년 이상의 경험을 가진 인물입니다. 사이먼의 경력에는 맥킨지 앤 컴퍼니, 백스터 헬스케어, 미 육군 보병 장교 등의 역할이 포함됩니다.
소테라 헬스의 회장 겸 CEO인 마이클 B. 페트라스 주니어는 사이먼의 합류에 대한 기대를 표명하며, 그의 상장 기업 CEO로서의 리더십 경험과 생명 과학 산업에서의 광범위한 상업적 및 전략적 전문성이 회사 성장에 중요한 자산이 될 것이라고 언급했습니다. 사이먼은 또한 글로벌 의료 기술 무역 협회인 아드바메드의 이사회의 일원으로 활동하고 있습니다.
Sotera Health Company (Nasdaq: SHC) a nommé Christopher Simon comme nouveau directeur indépendant au sein de son Conseil d'administration. Simon fera partie du Comité de Développement du Leadership et de Compensation. Il apporte plus de 30 ans d'expérience dans la transformation et la croissance des entreprises, occupant actuellement le poste de Président et CEO de Haemonetics (NYSE: HAE). Le parcours de Simon inclut des rôles au sein de McKinsey & Company, Baxter Healthcare et en tant qu'Officier d'Infanterie de l'Armée Américaine.
Michael B. Petras, Jr., Président et CEO de Sotera Health, a exprimé son enthousiasme concernant l'ajout de Simon, citant son expérience de leadership en tant que CEO d'une entreprise publique et son expertise commerciale et stratégique étendue dans le secteur des sciences de la vie comme des atouts précieux pour la croissance de l'entreprise. Simon siège également au conseil d'administration d'AdvaMed, une association commerciale mondiale de technologie médicale.
Sotera Health Company (Nasdaq: SHC) hat Christopher Simon als neuen unabhängigen Direktor in seinen Vorstand berufen. Simon wird im Ausschuss für Führungskräfteentwicklung und Vergütung tätig sein. Er bringt über 30 Jahre Erfahrung in der Geschäftstransformation und -wachstum mit und ist derzeit Präsident und CEO von Haemonetics (NYSE: HAE). Simons Hintergrund umfasst Positionen bei McKinsey & Company, Baxter Healthcare und als Infanterieoffizier der US-Armee.
Michael B. Petras, Jr., Vorsitzender und CEO von Sotera Health, äußerte Begeisterung über Simons Hinzukommen und nannte dessen Führungserfahrung als CEO eines öffentlichen Unternehmens sowie umfassende kommerzielle und strategische Expertise in der Biowissenschaftsbranche wertvolle Vermögenswerte für das Unternehmenswachstum. Simon ist außerdem Mitglied des Vorstands von AdvaMed, einer globalen Handelsvereinigung für Medizintechnologie.
- Appointment of Christopher Simon as a new independent director with over 30 years of industry experience
- Simon's current role as President and CEO of Haemonetics (NYSE: HAE)
- Simon's extensive background in strategy and management consulting with McKinsey & Company
- Addition of Simon's public company CEO experience to the board
- None.
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.
For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE: HAE), a global medical technology company, as well as a member of Haemonetics’ Board of Directors. Previously, Mr. Simon served as a Senior Partner of McKinsey & Company, a strategy and management consulting firm, where he led the Global Medical Products Practice. Prior to his career at McKinsey & Company, Mr. Simon served in commercial and operating roles at Baxter Healthcare Corporation, now Baxter International Inc., a healthcare company, and as a U.S. Army Infantry Officer in Korea and with the 1st Ranger Battalion. He brings more than 30 years of experience in helping businesses transform and grow.
“We are excited to welcome Chris to our Board of Directors,” said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. “Chris’s leadership experience as a public company CEO and his extensive commercial and strategic experience in the life sciences industry will serve as tremendous assets as we continue to grow.”
Mr. Simon also currently serves on the board of directors of AdvaMed, a global trade association of companies that develop, produce, manufacture and market medical technologies. Mr. Simon earned a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
| Contacts | |
| Jason Peterson Vice President Investor Relations & Treasurer, Sotera Health IR@soterahealth.com | |
| Kristin Gibbs Chief Marketing Officer, Sotera Health kgibbs@soterahealth.com |
Source: Sotera Health Company
FAQ
Who is the new board member appointed to Sotera Health (SHC)?
What committee will Christopher Simon serve on at Sotera Health (SHC)?
What is Christopher Simon's background before joining Sotera Health's (SHC) board?
How does Sotera Health (SHC) expect to benefit from Christopher Simon's appointment?
